Anti-17-1A monoclonal antibody 3622W94

Drug Profile

Anti-17-1A monoclonal antibody 3622W94

Alternative Names: 3622W94

Latest Information Update: 20 Jul 1999

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epithelial cell adhesion molecule inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Non-small cell lung cancer; Prostate cancer

Most Recent Events

  • 20 Jul 1999 Discontinued-II for Prostate cancer in USA (IV-infusion)
  • 20 Jul 1999 Discontinued-Preclinical for Non-small cell lung cancer in USA (IV-infusion)
  • 13 Aug 1998 A clinical study has been added to the adverse events, pharmacokinetics and immunogenicity sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top